Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-21 (globallegalchronicle.com)
Stoke Therapeutics' Collaboration with BioGen – Global Legal Chronicle
Fenwick & West represented Stoke Therapeutics, Inc. in the transaction.Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's…
Read more
2025-02-18 (novomomento.com.br)
Pfizer Brasil announces a new legal leader -
Pfizer Brasil announces a new legal leader read + news of economics, employment and market
Read more
2025-02-05 (law360.com)
Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order -
A Massachusetts federal judge on Tuesday said he was reminded of a grade school lesson in long division as he explained his reasoning behind granting class certification and cutting short the class period in a suit against drugmaker Biogen Inc. on the orders of the First Circuit.
Read more
2025-02-04 (juve-patent.com)
One week after Netherlands defeat Biogen takes the win in Germany -
Düsseldorf Regional Court prohibits generics manufacturers from launching generic versions of Biogen's Tecfidera on the German market.
Read more
2025-01-28 (juve-patent.com)
Generics companies successfully challenge Biogen's Dutch Tecfidera patent -
The District Court The Hague nullifed the Dutch part of Biogen's Tecfidera patent in a dispute with generics Mylan, Neuraxpharm and Sandoz.
Read more
2025-01-27 (bloomberglaw.com)
This Week in Chancery Court: Biogen, T-Mobile, Repsol SA
Biogen Inc. is fending off a lawsuit in the Delaware Chancery Court over its recent offer to buy out Sage Therapeutics, its collaborator on a postpartum depression drug.
Read more
2025-01-18 (pharmaphorum.com)
Sage sues Biogen after unsolicited takeover bid |
Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal
Read more
2025-01-18 (benzinga.com)
Deal Dispatch: Biden Punts TikTok Ban To Trump, Fate Hangs — Another Private Equity Owned Retailer Goes Bankrupt - AbbVie (NYSE:ABBV), Biogen (NASDAQ:BIIB) -
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Read more
2025-01-18 (bloomberglaw.com)
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent multiple sclerosis drug scheme, a federal appeals court said Friday.
Read more